Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
6910- FIS,    Exploring the therapeutic promise of fisetin: molecular mechanisms and clinical aspects in lung cancer
- in-vitro, Lung, NA
Apoptosis↑, TumCP↓, TumCMig↓, TumCI↓, TumAuto↝, ChemoSen↑, RadioS↑, chemoP↑, BioAv↓, Half-Life↓,
6906- FIS,  Rad,    Combining fisetin and ionizing radiation suppresses the growth of mammalian colorectal cancers in xenograft tumor models
- in-vivo, CRC, CT26 - in-vivo, CRC, HCT116
antiOx↑, Inflam↓, angioG↓, TumCI↓, TumCP↓, TumCG↓, RadioS↑,
6897- FIS,    Fisetin: A Dietary Antioxidant for Health Promotion
- Review, Nor, NA
*chemoPv↑, *neuroP↑, *antiOx↑, *GSH↑, *HO-1↑, *NRF2↑, angioG↓, TumCG↓, uPA↓, MMP1↓, tumCV↓, PTEN↑, PI3K↓, p‑Akt↓, AMPK↑, mTOR↓, EGFR↓, NF-kB↓, COX2/PTGS2↓, PGE2↓, Wnt↓, β-catenin/ZEB1↓, TCF↓, cycD1/CCND1↓, MMP7↓, RadioS↑, PSA↓, Securin↓, TumCCA↑, XIAP↓, *ERK↑, *p‑CREB↑, *memory↑, *GSH↑, *Inflam↓, *5LO↓,
6905- FIS,    Fisetin overcomes non-targetability of mutated KRAS induced YB-1 signaling in colorectal cancer cells and improves radiosensitivity by blocking repair of radiation-induced DNA double-strand breaks
- in-vitro, CRC, NA
RadioS↑,
6904- FIS,    Fisetin Inhibits Migration and Invasion of Human Cervical Cancer Cells by Down-Regulating Urokinase Plasminogen Activator Expression through Suppressing the p38 MAPK-Dependent NF-κB Signaling Pathway
- in-vitro, Cerv, NA
TumCP↓, Apoptosis↑, TumCI↓, TumCMig↓, uPA↓,
6911- FIS,    New Mitochondria-Targeted Fisetin Derivative Compromises Mitophagy and Limits Survival of Drug-Induced Senescent Breast Cancer Cells
- vitro+vivo, BC, NA
MMP↓, mt-ROS↑, Apoptosis↑, p‑AMPK↑, Akt↓, HSP90↓, PI3K↓, Akt↓, mTOR↓, TumCP↓, TumMeta↓, angioG↓, TumCD↑, selectivity↑, TumVol↓,
6912- FIS,    Cancer chemopreventive role of fisetin: Regulation of cell signaling pathways in different cancers
- Review, Var, NA
TumMeta↓, chemoPv↑, VEGF↓, VEGFR1↓, EGFR↓, Necroptosis↑, Hippo↝,
6913- FIS,    Fisetin inhibits tau aggregation by interacting with the protein and preventing the formation of β-strands
- in-vitro, AD, NA
*Aβ↓,
6914- FIS,    Fisetin inhibits inflammation and induces autophagy by mediating PI3K/AKT/mTOR signaling in LPS-induced RAW264.7 cells
- in-vitro, Nor, RAW264.7
*p‑PI3K↓, *p‑Akt↓, *p‑mTOR↓,
6915- FIS,  SRF,    Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
- in-vitro, Melanoma, NA
EMT↓, TumCP↓, PI3K↓, eff↑, N-cadherin↓, Vim↓, Fibronectin↓, E-cadherin↑, Snail↓, Twist↓, Slug↓, Zeb1↓, MMP2↓, MMP9↓, TumCI↓, TumMeta↓, ChemoSen↑,
6916- FIS,    Fisetin regulates TPA-induced breast cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways
- in-vitro, BC, MCF7
PCK1↓, ROS↓, ERK↓, MAPK↓, p38↓, NF-kB?,
6917- FIS,    Dietary flavonoid fisetin regulates aluminium chloride-induced neuronal apoptosis in cortex and hippocampus of mice brain
- in-vivo, AD, NA - in-vivo, Park, NA
*neuroP↑, *Dose↝, *Aβ↓, *ASK1↓, *p‑JNK↓, *P53↓, *Cyt‑c↓, *Casp9↓, *Bax:Bcl2↝,
6918- FIS,  Geld,  Radic,    HSP90 Inhibitors, Geldanamycin and Radicicol, Enhance Fisetin-Induced Cytotoxicity via Induction of Apoptosis in Human Colonic Cancer Cells
- in-vitro, CRC, COLO205
eff↑, cl‑Casp3↑, PARP↑, MMPs↓, cl‑Casp9↑, other↝,
6919- FIS,    Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysccharide-treated RAW264.7 cells
TumCP↓, Inflam↓, NO↓, iNOS↓, COX2/PTGS2↓, IL6↓, TNF-α↓, NF-kB↓, p‑cJun↓,
6920- FIS,    A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design
- Trial, BC, NA
Dose↝, cellSen?,
6921- FIS,    The Effects of Fisetin on Reducing Biological Aging: A Pilot Study
- Human, Nor, NA
*Dose↝, *AntiAge⇅,
6922- FIS,    Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin
- Review, Var, NA
*memory↑, *Inflam↓, *5LO↓, *lipid-P↓, *NF-kB↓, *antiOx↑, *GSH↑, *HO-1↑, *NRF2↑, *ROS↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumCMig↓, MMPs↓, PSA↓,
6901- FIS,    Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC
- in-vivo, HNSCC, CAL33
TumCG↓, TumCD↑, selectivity↑, TumCCA↑, CDC25↓, CDK1↓, CycB/CCNB1↓, P53↑, DNAdam↑, Apoptosis↑, γH2AX↑, cl‑PARP↑, other↝, JNK↑, PI3K↓, Akt↓, ERK↓, EGFR↓, STAT3↓, TumAuto↑, Dose↝, TumVol↓, Ki-67↓, cl‑Casp3↑, P21↓, p27/CDKN1B↓,
6900- FIS,    Fisetin targets phosphatidylinositol-3-kinase and induces apoptosis of human B lymphoma Raji cells
- in-vitro, lymphoma, NA
PI3K↓, Apoptosis↑, IAP2/BIRC3↓, mTOR↓, γH2AX↑, DNAdam↑,
6899- FIS,    Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1
Dose↝, tumCV↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↑, CDK4↑, CDK6↑, P21↑, p27/CDKN1B↑, Apoptosis↑, cl‑PARP↑, Cyt‑c↑, XIAP↓, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, PI3K↓, Akt↓,
6898- FIS,    Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
mTOR↓, Akt↓, AMPK↑, TumCG↓, mTORC1↓, mTORC2↓, 4E-BP1↑, LC3II↑, TumAuto↑,
6896- FIS,    Fisetin is a senotherapeutic that extends health and lifespan
- in-vivo, Nor, NA
*AntiAge↑, *cellSen↑, *selectivity⇅,
6895- FIS,    Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study
- in-vivo, Nor, NA
*neuroP↑, *cardioP↑, *chemoPv↑, *AntiDiabetic↑, *Inflam↓, *ROS↓, *BioAv↓, *BioAv↑, *eff↑, *Half-Life↓,
6902- FIS,    Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
P53↑, NF-kB↓, TumCP↓, Apoptosis↑, TumCCA↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK4↓, CDK2↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓,
6994- FIS,    Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells
- in-vitro, Colon, HT29
TumCG↓, TumCCA↑, CDK2↓, CDK4↓, cycE/CCNE↓, cycD1/CCND1↓, P21↑,
5392- FIS,  AsP,    Fisetin topical delivery via ascorbyl palmitate/hyaluronan-enhanced limosomes: a novel paradigm for preventing UVB-induced skin photoaging
- in-vivo, Nor, NA
eff↑, *antiOx↑, *MMP9↓, *TNF-α↓, *NF-kB↓, *SOD↑, *Catalase↑, *AntiAge↑, *Inflam↓, *JNK↓,
2851- FIS,    Apoptosis induction in breast cancer cell lines by the dietary flavonoid fisetin
- in-vitro, BC, MDA-MB-468 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, BC, T47D - in-vitro, BC, SkBr3 - in-vitro, Nor, NA
tumCV↓, selectivity↑, TumCCA↑, Apoptosis↑, ROS∅,
2847- FIS,    Fisetin-induced cell death, apoptosis, and antimigratory effects in cholangiocarcinoma cells
- in-vitro, CCA, NA
tumCV↓, ChemoSen↑, TumCMig↓, ROS↑, TumCI↓, angioG↓, CDK2↓, PI3K↓, Akt↓, mTOR↓, EGFR↓, Casp↑, mTORC1↓, mTORC2↑, cycD1/CCND1↓, cycE/CCNE↓, MMP2↓, MMP9↓, ER Stress↑, Ca+2↑, eff↓,
2848- FIS,    Fisetin alleviates cellular senescence through PTEN mediated inhibition of PKCδ-NOX1 pathway in vascular smooth muscle cells
- in-vitro, Nor, NA
*ROS↓, *PTEN↑, *PKCδ↑, *Inflam↓,
2849- FIS,    Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells
- in-vitro, Melanoma, U266
TumCD↑, TumCCA↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, p‑Akt↓, p‑mTOR↓, ROS↑, eff↓,
2850- FIS,    Fisetin regulates TPA-induced breast Cancer cell invasion by suppressing matrix metalloproteinase-9 activation via the PKC/ROS/MAPK pathways
- in-vitro, BC, MCF7
TumCI↓, PKCδ↓, ROS↓, ERK↑, p38↓, NF-kB↓, MMP9↓,
2852- FIS,    A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms
- Review, CRC, NA
Risk↓, P53↑, MDM2↓, COX2/PTGS2↓, Wnt↓, NF-kB↓, CDK2↓, CDK4↓, p‑RB1↓, cycE/CCNE↓, P21↑, NRF2↓, ROS↑, Casp8↑, Fas↑, TRAIL↑, DR5↑, MMP↓, Cyt‑c↑, selectivity↑, P450↝, GSTs↝, RadioS↑, Inflam↓, β-catenin/ZEB1↓, EGFR↓, TumCCA↑, ChemoSen↑,
2846- FIS,    Fisetin protects against cardiac cell death through reduction of ROS production and caspases activity
- in-vitro, Nor, NA
*cardioP↑, *ROS↓, *Casp↓, *DNAdam↓,
2853- FIS,    Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells
- in-vitro, Thyroid, TPC-1
Apoptosis↑, ROS↑, MMP↓, TumCCA↑, Casp3↑, Casp8↑, Casp9↑, JAK1↓, STAT3↓,
2854- FIS,    New Perspectives for Fisetin
- Review, Var, NA - Review, Stroke, NA
Inflam↓, ChemoSen↑, chemoPv↑, eff↑, memory↑, neuroP↑, *Dose↑, BioAv↓, BBB↑,
2855- FIS,    Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells
- in-vitro, RCC, Caki-1
TumCCA↑, cl‑PARP↑, Apoptosis↑, Casp↑, P53↑, DR5↑, CHOP/DDIT3↑, ROS↑, ER Stress↑, ATF4↑, XBP-1↑, eff∅,
2856- FIS,    N -acetyl- L -cysteine enhances fisetin-induced cytotoxicity via induction of ROS-independent apoptosis in human colonic cancer cells
- in-vitro, Colon, COLO205
eff↑, ROS↑, tumCV↓, Casp3↑, Bcl-2↓, MMP↓, eff↑,
2857- FIS,    A review on the chemotherapeutic potential of fisetin: In vitro evidences
- Review, Var, NA
COX2/PTGS2↓, PGE2↓, EGFR↓, Wnt↓, β-catenin/ZEB1↓, TCF↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, Akt↓, mTOR↓, ACC↑, Cyt‑c↑, Diablo↑, cl‑Casp8↑, Fas↑, DR5↑, TRAIL↑, Securin↓, CDC2↓, CDC25↓, HSP70/HSPA5↓, CDK2↓, CDK4↓, cycD1/CCND1↓, MMP2↓, uPA↓, NF-kB↓, cFos↓, cJun↓, MEK↓, p‑ERK↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↓, NF-kB↑, ROS↑, DNAdam↑, MMP↓, CHOP/DDIT3↑, eff↑, ChemoSen↑,
2858- FIS,    Fisetin inhibits cell migration via inducing HO-1 and reducing MMPs expression in breast cancer cell lines
- in-vitro, BC, 4T1
HO-1↑, NRF2↑, MMP2↓, MMP9↓,
2859- FIS,    The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways
- in-vitro, Liver, HepG2 - NA, Colon, Caco-2
TumCG↓, other↝, Casp3↑, Casp7↑, PGE2↓, GSTs↓, Wnt↓, EGFR↓, NF-kB↓, COX2/PTGS2↓, P53↑, P21↑, P450↓,
2860- FIS,    Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3 - in-vitro, Nor, hTERT-HPNE - in-vivo, NA, NA
AMPK↑, mTOR↑, UPR↑, ER Stress↑, selectivity↑, TumCP↓, PERK↑, ATF4↑, ATF6↑,
2861- FIS,    The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress
- Review, Nor, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *ROS↓, *neuroP↑, *NO↑, BioAv↝, *BBB↑, *toxicity↑, *eff↑, *GSH↑, *SOD↑, *Aβ↓, *12LOX↓, *COX2/PTGS2↓, *Catalase↑, *Inflam↓, *TNF-α↓, *IL6↑, *lipid-P↓, NF-kB↓, IL1β↓, NRF2↑, HO-1↑, GSTs↑, cognitive↑, *BDNF↑,
2862- FIS,    Fisetin averts oxidative stress in pancreatic tissues of streptozotocin-induced diabetic rat
- in-vivo, Diabetic, NA
*BG↓, *NF-kB↓, *IL1β↓, *NO↓, *Insulin↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑,
2844- FIS,    Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells
- in-vitro, OS, U2OS
tumCV↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, BAX↑, BAD↑, Bcl-2↓, Bcl-xL↓, PI3K↓, Akt↓, ERK↓, p‑JNK↑, p‑cJun↑, p‑p38↑, ROS↑, MMP↓, mTORC1↓, PTEN↑, p‑GSK‐3β↓, GSK‐3β↑, NF-kB↓, IKKα↑, Cyt‑c↑,
2845- FIS,    Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy
- Review, Var, NA
PI3K↓, Akt↓, mTOR↓, p38↓, *antiOx↑, *neuroP↑, Casp3↑, Bcl-2↓, Mcl-1↓, BAX↑, BIM↑, BAD↑, AMPK↑, ACC↑, DNAdam↑, MMP↓, eff↑, ROS↑, cl‑PARP↑, Cyt‑c↑, Diablo↑, P53↑, p65↓, Myc↓, HSP70/HSPA5↓, HSP27↓, COX2/PTGS2↓, Wnt↓, EGFR↓, NF-kB↓, TumCCA↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycA1/CCNA1↓, P21↑, MMP2↓, MMP9↓, TumMeta↓, MMP1↓, MMP3↓, MMP7↓, MET↓, N-cadherin↓, Vim↓, Snail↓, Fibronectin↓, E-cadherin↑, uPA↓, ChemoSen↑, EMT↓, Twist↓, Zeb1↓, cFos↓, cJun↓, EGF↓, angioG↓, VEGF↓, eNOS↓, *NRF2↑, HO-1↑, NRF2↓, GSTs↓, ATF4↓,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27/CDKN1B↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2/PTGS2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
2826- FIS,    Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway
- in-vitro, BC, MDA-MB-453
Apoptosis↑, p‑ENO1↓, DNAdam↑, PI3K↑, p‑Akt↑, HER2/EBBR2↓,
2827- FIS,    The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, neuroP↑, hepatoP↑, RenoP↑, cycD1/CCND1↓, TumCCA↑, MMPs↓, VEGF↓, MAPK↓, NF-kB↓, angioG↓, Beclin-1/ATG6↑, LC3s↑, ATG5↑, Bcl-2↓, BAX↑, Casp↑, TNF-α↓, Half-Life↓, MMP↓, mt-ROS↑, cl‑PARP↑, CDK2↓, CDK4↓, Cyt‑c↑, Diablo↑, DR5↑, Fas↑, PCNA↓, Ki-67↓, p‑H3↓, chemoP↑, Ca+2↑, Dose↝, CDC25↓, CDC2↓, CHK1↑, Chk2↑, ATM↑, PCK1↓, RAS↓, p‑p38↓, Rho↓, uPA↓, MMP7↓, MMP13↓, GSK‐3β↑, E-cadherin↑, survivin↓, VEGFR2/KDR/Flk1↓, IAP2/BIRC3↓, STAT3↓, JAK1↓, mTORC1↓, mTORC2↓, NRF2↑,
2828- FIS,    Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review
- Review, Var, NA
*neuroP↑, *antiOx↑, *Inflam↓, RenoP↑, COX2/PTGS2↓, Wnt↓, EGFR↓, NF-kB↓, Casp3↑, Ca+2↑, Casp8↑, TumCCA↑, CDK1↓, PI3K↓, Akt↓, mTOR↓, MAPK↓, *P53↓, *P21↓, *p16↓, mTORC1↓, mTORC2↓, P53↑, P21↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, BAX↑, Bcl-2↓, PCNA↓, HER2/EBBR2↓, Cyt‑c↑, MMP↓, cl‑Casp9↑, MMP2↓, MMP9↓, cl‑PARP↑, uPA↓, DR4↑, DR5↑, ROS↓, AIF↑, CDC25↓, Dose↑, CHOP/DDIT3↑, ROS↑, cMyc↓, cardioP↑,

Showing Research Papers: 3851 to 3900 of 8269
Prev Page 78 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   GSTs↓, 2,   GSTs↑, 1,   GSTs↝, 1,   HO-1↑, 3,   NRF2↓, 2,   NRF2↑, 3,   ROS↓, 4,   ROS↑, 12,   ROS∅, 1,   mt-ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   CDC2↓, 2,   CDC25↓, 4,   EGF↓, 1,   MEK↓, 1,   MMP↓, 11,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↑, 3,   AMPK↑, 6,   p‑AMPK↑, 1,   cMyc↓, 1,   p‑ENO1↓, 1,   PCK1↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 13,   p‑Akt↓, 2,   p‑Akt↑, 1,   Apoptosis↑, 13,   BAD↑, 4,   Bak↑, 1,   BAX↑, 7,   Bcl-2↓, 9,   Bcl-xL↓, 2,   BIM↑, 3,   Casp↑, 4,   Casp3↑, 10,   cl‑Casp3↑, 2,   Casp7↑, 2,   Casp8↑, 6,   cl‑Casp8↑, 1,   Casp9↑, 5,   cl‑Casp9↑, 2,   Chk2↑, 1,   Cyt‑c↑, 8,   Diablo↑, 4,   DR4↑, 1,   DR5↑, 5,   Fas↑, 3,   Hippo↝, 1,   IAP2/BIRC3↓, 2,   iNOS↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 3,   Mcl-1↓, 3,   MDM2↓, 1,   Myc↓, 1,   Necroptosis↑, 1,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 2,   p38↓, 3,   p‑p38↓, 1,   p‑p38↑, 1,   survivin↓, 1,   TRAIL↑, 2,   TumCD↑, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 2,   p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 3,   p‑cJun↓, 1,   p‑cJun↑, 1,   p‑H3↓, 1,   other↝, 3,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1,   CHOP/DDIT3↑, 3,   ER Stress↑, 4,   GRP78/BiP↑, 1,   HSP27↓, 2,   HSP70/HSPA5↓, 3,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3II↑, 1,   LC3s↑, 1,   TumAuto↑, 2,   TumAuto↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   CHK1↑, 1,   DNAdam↑, 6,   P53↑, 8,   PARP↑, 1,   cl‑PARP↑, 9,   PCNA↓, 2,   γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 10,   CDK2↑, 1,   CDK4↓, 9,   CDK4↑, 1,   cycA1/CCNA1↓, 3,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 11,   cycE/CCNE↓, 6,   P21↓, 1,   P21↑, 8,   p‑RB1↓, 1,   Securin↓, 2,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↑, 1,   cFos↓, 3,   EMT↓, 4,   ERK↓, 4,   ERK↑, 1,   p‑ERK↓, 1,   GSK‐3β↑, 2,   p‑GSK‐3β↓, 1,   mTOR↓, 9,   mTOR↑, 1,   p‑mTOR↓, 1,   mTORC1↓, 6,   mTORC2↓, 3,   mTORC2↑, 1,   PI3K↓, 13,   PI3K↑, 1,   PTEN↑, 2,   RAS↓, 1,   STAT3↓, 3,   TCF↓, 1,   TCF↑, 1,   TumCG↓, 6,   Wnt↓, 7,  

Migration(tgid=13) ⓘ

Ca+2↑, 4,   E-cadherin↓, 1,   E-cadherin↑, 4,   Fibronectin↓, 3,   Ki-67↓, 2,   MET↓, 1,   MMP1↓, 3,   MMP13↓, 1,   MMP2↓, 7,   MMP3↓, 1,   MMP7↓, 3,   MMP9↓, 8,   MMPs↓, 3,   N-cadherin↓, 4,   PKCδ↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 3,   TumCI↓, 7,   TumCMig↓, 5,   TumCP↓, 9,   TumMeta↓, 4,   Twist↓, 2,   uPA↓, 8,   VEGFR1↓, 1,   Vim↓, 4,   Zeb1↓, 2,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   ATF4↓, 1,   ATF4↑, 3,   EGFR↓, 10,   eNOS↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

cellSen?, 1,   COX2/PTGS2↓, 8,   IKKα↑, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 4,   JAK1↓, 2,   NF-kB?, 1,   NF-kB↓, 14,   NF-kB↑, 1,   p65↓, 1,   PGE2↓, 4,   PSA↓, 2,   TNF-α↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,   CDK6↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 8,   Dose↑, 1,   Dose↝, 4,   eff↓, 2,   eff↑, 11,   eff∅, 1,   Half-Life↓, 2,   Half-Life↝, 2,   P450↓, 1,   P450↝, 1,   RadioS↑, 6,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 10,   HER2/EBBR2↓, 2,   IL6↓, 1,   Ki-67↓, 2,   Myc↓, 1,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoP↑, 2,   chemoPv↑, 2,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 2,   RenoP↑, 2,   Risk↓, 1,   TumVol↓, 2,  
Total Targets: 221

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 8,   Catalase↑, 3,   GPx↑, 1,   GSH↑, 5,   GSTs↑, 1,   HO-1↑, 3,   lipid-P↓, 2,   NRF2↑, 4,   ROS↓, 6,   SOD↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Insulin↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   p‑cMyc↑, 1,   p‑CREB↑, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   ASK1↓, 1,   Bax:Bcl2↝, 1,   Casp↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   JNK↓, 1,   p‑JNK↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,   p16↓, 1,   P53↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 2,   p‑mTOR↓, 1,   p‑PI3K↓, 1,   PTEN↑, 1,  

Migration(tgid=13) ⓘ

5LO↓, 2,   MMP9↓, 1,   PKCδ↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   NO↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

cellSen↑, 1,   COX2/PTGS2↓, 1,   IL1β↓, 1,   IL6↑, 1,   Inflam↓, 10,   NF-kB↓, 3,   TNF-α↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↑, 1,   Dose↝, 2,   eff↑, 2,   Half-Life↓, 1,   selectivity⇅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BG↓, 1,   IL6↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 2,   AntiAge⇅, 1,   AntiDiabetic↑, 1,   cardioP↑, 2,   chemoPv↑, 2,   memory↑, 2,   neuroP↑, 7,   toxicity↑, 1,  
Total Targets: 63

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page